Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cell marker eyed as early warning for hardened heart arteries in kidney disease

NCT ID NCT07811505

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

People with advanced chronic kidney disease often develop calcium buildup in their coronary arteries, which raises the risk of heart problems. Researchers want to know whether a protein called CXCR2 on white blood cells can predict whose arteries will harden fastest. About 100 adults with stage IV or V kidney disease will give blood samples and have chest CT scans at the start, after one year, and after three years. The study measures CXCR2 levels and compares them with changes in coronary calcium scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If CXCR2 levels track with worsening artery calcification, doctors could one day use a simple blood test to spot kidney disease patients at highest risk and target the pathway with new drugs.
What could go wrong
This is an observational study with no treatment, so it cannot prove that CXCR2 causes calcification. A link in 100 people may not hold up in larger groups, and three years may be too short to see meaningful changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \> 18 years * CKD defined by eGFR \< 30 mL/min/1,73m² * signed inform consent Exclusion Criteria: * patients on dialysis, * kidney transplant recipients, * current or recent (within 30 days) infection, * inflammatory diseases, * active cancer treatment, * use of immunosuppressive agents, * presence of coronary stents or aortic valve protheses, * inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease Coronary arteries calcifications CXCR2 expression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU Amiens

    Amiens, 80480, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.